Abstract: Polymeric compounds having spatially controlled bioconjugation sites are described. Functionalization is achieved by selective co-terminal chain extension of polymer chains by radical polymerization, such as reversible addition-fragmentation chain transfer (RAFT) polymerization.
Type:
Application
Filed:
December 8, 2009
Publication date:
December 15, 2011
Applicants:
PhaseRx, Inc., University of Washington
Inventors:
Patrick S. Stayton, Allan S. Hoffman, Anthony J. Convertine, Scott M. Henry, Robert W. Overell, Paul H. Johnson
Abstract: Conjugates of a polymer having attached thereto an angiogenesis targeting moiety and a therapeutically active agent such as an anti-cancer agent or anti-angiogenesis agent, and processes of preparing same are disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment of angiogenesis-related medical conditions such as cancer and cancer metastases are also disclosed.
Type:
Application
Filed:
May 21, 2009
Publication date:
November 24, 2011
Applicant:
Fundacion de la Communidad Valenciana Centro de Investigacion principe felipe
Inventors:
Ronit Satchi-Fainaro, Maria Jesus Vincent Docon
Abstract: Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and an oligoaspartate bone targeting agent, and processes of preparing same, are further disclosed. Pharmaceutical compositions containing these conjugates and uses thereof in the treatment and monitoring of bone related disorders are also disclosed.
Type:
Application
Filed:
May 21, 2009
Publication date:
April 14, 2011
Applicants:
Ramot at Tel-Aviv University Ltd., University of Utah Research Foundation
Inventors:
Ronit Satchi-Fainaro, Ehud Segal, Jindrich Kopecek, Pavla Kopeckova, Huaizhong Pan
Abstract: The present invention relates to a multi-conjugate of small interfering RNA (siRNA) and a preparing method of the same, more precisely a multi-conjugate of siRNA prepared by direct binding of double stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross-linking agent or a polymer, and a preparing method of the same. The preparing method of a siRNA multi-conjugate of the present invention is characterized by simple and efficient reaction and thereby the prepared siRNA multi-conjugate of the present invention has high molecular weight multiple times the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier and high gene delivery efficiency.
Type:
Application
Filed:
April 29, 2009
Publication date:
February 24, 2011
Applicant:
KOREA ADVANCE INSTITUTE OF SCIENCE AND TECHNOLOGY
Abstract: Disclosed is a composition for the delivery of nucleic acid to target cells or tissues, which comprises a polycationically charged polymer as a carrier of nucleic acid. The polycationically charged polymer is a polymer which may comprise a charged polymer segment having a main chain based on poly(amino acid), polysaccharide, polyester, polyether, polyurethane or vinyl polymer and having, as a side chain, a group of formula —NH—(CH2)a—(NH(CH2)2)e—NH2 (wherein a and e independently denote an integer of 1 to 5) which is connected to the main chain either directly or via a linker. The disclosed composition has low toxicity, and has a high efficiency in introducing nucleic acid into cells.
Abstract: Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes and/or the delivery of pharmaceutically active compounds to mucosal surfaces for topical treatment or transfer to the systemic circulation.
Type:
Grant
Filed:
February 15, 2002
Date of Patent:
June 16, 2009
Assignee:
Access Pharmaceuticals, Inc.
Inventors:
Jeremy E. Jacob, David P. Nowotnik, Christiane M. Baud
Abstract: Stable, viscous, mucoadhesive aqueous compositions which are useful for the prevention and treatment of ulcerative, inflammatory, and/or erosive disorders of mucous membranes, especially mucositis.
Type:
Grant
Filed:
August 15, 2002
Date of Patent:
June 9, 2009
Assignee:
Access Pharmaceuticals, Inc.
Inventors:
Jeremy E. Jacob, David P. Nowotnik, Christiane M. Baud
Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
Type:
Grant
Filed:
April 5, 2005
Date of Patent:
April 3, 2007
Assignee:
Yeda Research and Development Co., Ltd.
Inventors:
Eliezer Konfino, Michael Sela, Dvora Teitelbaum, Ruth Arnon
Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
Type:
Grant
Filed:
July 10, 2003
Date of Patent:
September 6, 2005
Assignee:
Yeda Research & Development
Inventors:
Eliezer Konfino, Michael Sela, Dvora Teitelbaum, Ruth Arnon
Abstract: The present invention is directed toward an injectable, single- or multiple-component polymeric liquid precursor of an in situ-forming, non-absorbable, flexible, and resilient hydrogel or semi-solid that can be used in non-surgical, minimally invasive treatment of herniated disc.
Abstract: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.
Type:
Application
Filed:
March 28, 2003
Publication date:
July 22, 2004
Inventors:
Alexander Schwarz, Guerard W. Byrne, Thomas A. Davis, Lisa E. Diamond, John S. Logan
Abstract: The invention provides immunomodulatory compounds and methods for immunomodulation of cells and individuals using the immunomodulatory compounds.
Abstract: Methods of preparing vancomycin-polymer conjugates are disclosed. In preferred aspects, polymer residues which are preferably releasable, are selectively attached to the sugar amino and/or N-methyl amino groups of vancomycin and related compounds. Vancomycin-polymer conjugates made by the methods and methods of treatment using the conjugates are also disclosed.
Abstract: The present invention relates to compositions and methods involving biocompatible dendrimers. In particular, the present invention provides dendrimeric copolymers with poly(propyleneimine) (POPAM) interiors and poly(amidoamine) (PAMAM) exteriors for use in transfection and imaging applications.
Type:
Application
Filed:
May 8, 2003
Publication date:
June 10, 2004
Inventors:
James R. Baker, Blake J. Roessler, Anna U. Bielinska
Abstract: Glucoside and glucuronide derivatives of hydromorphone, dihydromorphine, and dihydroisomorphine and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising a glucoside or glucuronide derivative of hydromorphone, dihydromorphine, or dihydroisomorphine or a pharmaceutically acceptable salt thereof; and methods for treating or preventing pain in a patient comprising administering to a patient in need thereof a glucoside or glucuronide derivative of hydromorphone, dihydromorphine, or dihydroisomorphine or a pharmaceutically acceptable salt thereof are disclosed.
Abstract: A reagent and related method for use in passivating a biomaterial surface, the reagent including a latent reactive group and a bifunctional aliphatic acid (e.g., fatty acid), in combination with a spacer group linking the latent reactive group to the aliphatic acid in a manner that preserves the desired function of each group. Once bound to the surface, via the latent reactive group, the reagent presents the aliphatic acid to the physiological environment, in vivo, in a manner (e.g., concentration and orientation) sufficient to hold and orient albumin.
Type:
Application
Filed:
April 24, 2003
Publication date:
November 20, 2003
Applicant:
SurModics, Inc
Inventors:
Patrick E. Guire, Aron B. Anderson, Richard A. Amos, Terrence P. Everson
Abstract: The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.
Type:
Grant
Filed:
December 14, 2001
Date of Patent:
September 16, 2003
Assignee:
Yeda Research and Development Co., Ltd.
Inventors:
Eliezer Konfino, Michael Sela, Dvora Teitelbaum, Ruth Arnon
Abstract: One aspect of the present invention relates to novel compounds that can be used to prepare radiolabeled compounds in an effective manner. A second aspect of the present invention relates to a method of synthesizing radiolabeled compounds.
Abstract: The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount.
Type:
Application
Filed:
December 19, 2001
Publication date:
October 24, 2002
Applicant:
GelTex Pharmaceuticals, Inc.
Inventors:
Chad Cori Huval, Stephen Randall Holmes-Farley, John S. Petersen, Pradeep K. Dhal
Abstract: To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing. moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.
Abstract: The invention relates to polymeric conjugates of 20-O-[glycyl-aminoacyl-glycyl]-camptothecins and a process for producing the same.
Abstract: An antiviral compound comprises a dendrimer such as a polyamidoamine or polyly sine dendrimer having a plurality of terminal groups, wherein at least one of the terminal groups has an anionic- or cationic-containing moiety bonded thereto, particularly a sulfonic acid-containing, carboxylic acid-containing or trimethylammonium-containing moiety or the like.